Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Reduced Annexin A3 in schizophrenia

Texto completo
Autor(es):
Joaquim, Helena P. G. [1, 2] ; Costa, Alana Caroline [1, 2] ; Serpa, Mauricio Henriques [3] ; Talib, Leda L. [1, 2] ; Gattaz, Wagner F. [1, 2]
Número total de Autores: 5
Afiliação do(s) autor(es):
[1] Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Nacl Biomarcadores Neuropsiquiatria INBION, Sao Paulo - Brazil
[2] Univ Sao Paulo, Lab Neurosci LIM 27, Dept & Inst Psychiat, Rua Dr Ovidio Pires de Campos 785, 3 Andar, BR-05403010 Sao Paulo, SP - Brazil
[3] Univ Sao Paulo, Dept & Inst Psychiat, Lab Psychiat Neuroimaging LIM 21, Med Sch, Sao Paulo - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE; v. 270, n. 4, p. 489-494, JUN 2020.
Citações Web of Science: 0
Resumo

The cellular and molecular mechanisms underlying onset and development of schizophrenia have not yet been completely elucidated, but the association of disturbed neuroplasticity and inflammation has gained particular relevance recently. These mechanisms are linked to annexins functions. ANXA3, particularly, is associated to inflammation and membrane metabolism cascades. The aim was to determine the ANXA3 levels in first-onset drug-naive psychotic patients. We investigated by western blot the protein expression of annexin A3 in platelets of first-onset, drug-naive psychotic patients (diagnoses according to DSM-IV: 28 schizophrenia, 27 bipolar disorder) as compared to 30 age- and gender-matched healthy controls. Annexin A3 level was lower in schizophrenia patients as compared to healthy controls (p < 0.001) and to bipolar patients (p < 0.001). Twenty out of 28 schizophrenic patients had undetectable annexin A3 levels, as compared to none from the bipolar and none from the control subjects. ANXA3 was reduced in drug-naive patients with schizophrenia. ANXA3 affects neuroplasticity, inflammation and apoptosis, as well as it modulates membrane phospholipid metabolism. All these processes have been discussed in regard to the biology of schizophrenia. In face of these data, we feel that further studies with larger samples are warranted to investigate the possible role of reduced ANXA3 as a possible risk marker for schizophrenia. (AU)

Processo FAPESP: 14/50873-3 - INCT 2014: Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN)
Beneficiário:Wagner Farid Gattaz
Linha de fomento: Auxílio à Pesquisa - Temático
Processo FAPESP: 14/20913-3 - Determinação de fosfolípides plasmáticos nas doenças neuropsiquiátricas
Beneficiário:Alana Caroline Costa
Linha de fomento: Bolsas no Brasil - Mestrado